Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience Corp. announces promising results from a study evaluating its DehydraTECH technology with the GLP-1 diabetes drug, semaglutide, preserving its monomeric form, essential for effective systemic delivery. The research, in collaboration with Canada’s National Research Council, suggests DehydraTECH might match a key property of the commercially successful Rybelsus without using its expensive proprietary ingredient.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.